Replimune (NASDAQ:REPL) Shares Soar as FDA Panel Supports RP1 Despite Ongoing Evidence Debate

NEW YORK, July 31, 2026, 17:13 EDT — Trading on Wall Street has ended for the day.

Replimune finished at $11.20, rising 107.0%, with trading volume 7.5 times its average.
FDA advisers voted 10–3 that the efficacy data for RP1 was both evaluable and clinically significant.
The FDA recorded a primary response rate of 15.7%, compared to the 33.6% reported by Replimune.

Replimune stock finished Friday at $11.20, gaining 107.0%. The surge came after an FDA advisory panel voted 10–3 in favor of RP1. The company’s reported market capitalization jumped by about $485 million to $940.2 million. Trading volume was 33.38 million shares, 7.5 times the usual level.

The ballot focused on the reliability of the data rather than on granting approval. Advisers determined that the IGNYTE efficacy findings could be assessed and were clinically significant. The FDA has set Sunday, August 2, as its target decision date. The agency previously turned down the application on two occasions.

The main message for investors is the weight placed on regulatory uncertainty. An initial estimate of economic share factors in 14.06 million reported pre-funded warrants. Based on this, the increase on Friday contributed approximately $568 million to equity value. The pipeline value, adjusted for net cash, increased by 2.65 times.

Valuation measure	Pre-panel reference	Friday close	Change
Share price	$5.41	$11.20	up 107.0%
Economic shares	98.09 million	98.09 million	unchanged
Economic equity value	$530.7 million	$1.099 billion	rise of $567.9 million
Less March 31 net cash	$185.6 million	$185.6 million	unchanged
Implied pipeline and operations value	$345.1 million	$913.0 million	increase of 164.6%, or 2.65 times

Initial estimate: factors in common stock and pre-funded warrants, omits options and restricted stock units, and assumes March 31 net cash remains unchanged.

Despite Friday’s rally, shares recorded a sharp reversal over the week. The stock ended 15.5% higher compared to its July 24 close. Earlier, shares had dropped 44.8% as of Tuesday after FDA staff released its review.

Trading reference	Close	Change	Volume	Context
July 24	$9.70	—	3.27 million	Previous week’s closing price
July 28	$5.35	-44.8% from July 24	24.02 million	FDA staff releases documents
July 29	$5.41	+1.1% on the day	14.30 million	Reference before the panel
July 31	$11.20	+107.0%	33.38 million	Closing price following the vote
Weekly result	—	+15.5%	—	July 24–July 31

The main issue concerns the difference in response rates. Replimune stated an objective response rate of 33.6%. In contrast, the FDA’s primary review found the rate to be 15.7%. The median duration of response dropped by 10.7 months.

IGNYTE assessment	Patients	Responders	Objective response rate	Median response duration
Replimune assessment	140	47	33.6% (25.8%–42.0%)	24.8 months
FDA main analysis	140	22	15.7% (10.1%–22.8%)	14.1 months
FDA reanalysis	89	22	24.7% (16.2%–35.0%)	14.1 months

The FDA determined that 53% of sponsor-defined responders did not have a non-injected target lesion. All 140 patients were kept in the analysis, but many responses were reclassified. This lessened the strength of evidence for an effect beyond tumors treated with local injection. Attribution was further complicated by nivolumab.

Evan Seigerman, analyst at BMO Capital Markets, part of Bank of Montreal NYSE:BMO, stated that the testimony presented a “compelling case for RP1 despite FDA criticism.” He described accelerated approval as “almost certain.” However, panel member John Carrino described the data as “really messy.” Reuters

Replimune CEO Sushil Patel described the vote as “an important step forward.” He stated that the company will continue its collaboration with the FDA ahead of the deadline. Replimune Group Inc.

RP1 is administered directly into tumors and used in combination with Bristol-Myers Squibb Co.’s NYSE:BMY Opdivo. Panel members cited Iovance Biotherapeutics, Inc.’s NASDAQ:IOVA Amtagvi as the other treatment option available. Iovance shares dropped 13.4% on Friday as Replimune’s stock price doubled. The contrasting stock performance does not indicate direct replacement.

Comparison	RP1 plus Opdivo	Amtagvi
Company	Replimune and Bristol-Myers Squibb	Iovance
Regulatory status	FDA verdict awaited	Received accelerated approval
Treatment format	Oncolytic therapy injected into tumor with nivolumab	T cells grown from patient’s tumor
Care requirements	Labeling details not yet determined	Requires hospital stay, lymphodepletion and IL-2 after infusion
July 31 stock move	REPL +107.0%	IOVA -13.4%

Amtagvi needs tumor tissue to be collected and produced for each patient. The drug’s label specifies that treatment must occur in a hospital with intensive care facilities. Panelist Hussein Tawbi remarked that RP1 seemed “a lot safer, a lot easier.” fda.gov

Approval would reveal another limitation: launch preparedness. After April’s rejection, Replimune reduced its workforce by around 55%. The company currently lacks internal teams for sales, marketing, or commercialization. Restoring these capabilities will require both financial resources and time.

As of March 31, cash and short-term investments totaled $268.9 million, while debt stood at $83.3 million. Operating cash usage for the fiscal year amounted to $280.3 million. Management forecasted sufficient funding into early 2027, factoring in expected launch scale-up.

FDA’s decision deadline comes ahead of Monday’s normal market hours. Investors are set to assess the approval outcome, details on labeling, and requirements for confirmatory trials. Information regarding launch schedule and financing strategy could become relevant right away.

Risks are still focused. The FDA does not have to follow the panel’s recommendation. A further rejection, limited label, or strict post-market conditions could undo Friday’s advance. Even with approval, risks around funding and implementation remain.

The panel’s vote altered the framing of the question, leaving the dataset unchanged. Investors are now factoring in increased odds of approval along with tougher launch challenges. Both expectations will be tested at Sunday’s FDA deadline.

TS2 TECH • EXTENDED COVERAGE

Further analysis

Editorial insight

What caused Replimune stock to surge over 100% on Friday?

U.S. markets will remain shut on Saturday, with Friday’s $11.20 closing price standing as the most recent. Shares of Replimune jumped 107%, compared to a 1.0% gain for the Nasdaq Composite. Barron's Trading volume hit 33.4 million shares. The rally came after investors responded to the FDA panel’s 10-3 vote endorsing the efficacy of IGNYTE. Replimune Group Inc. The company ended the session with a market value of about $1 billion. The move reflected regulatory repricing, rather than a broader market surge.

Does the FDA panel’s decision increase the chances of RP1 being approved?

A 10-3 vote increased the likelihood of approval but did not grant approval for RP1. The FDA reviews committee recommendations but retains the authority for the final regulatory decision. The current target action date is Sunday, August 2, 2026. fda.gov Replimune was previously issued complete response letters in July 2025 and April 2026. These communications focused on whether IGNYTE demonstrated significant, attributable efficacy. SEC Prospects for approval have improved, though approval is not guaranteed.

What do the primary efficacy results for RP1 indicate?

Replimune achieved a 33.6% objective response rate among 140 patients, with 23 complete responses and 24 partial responses reported. The median duration of response reached 24.8 months. fda.gov Follow-up data from the company indicated median overall survival of 32.9 months, while three-year survival stood at 47.8% in the study cohort. Replimune Group Inc. The FDA maintains single-arm survival results do not confirm a treatment effect. fda.gov

What caused the FDA's efficacy calculation to be significantly lower than Replimune's figures?

FDA’s primary review reported 22 responders out of 140 total patients, yielding a 15.7% response rate and a 14.1-month median duration of response. A sensitivity analysis identified a 24.7% response rate among 89 evaluable patients. fda.gov The difference comes from differing views on injected lesions and RECIST response assessment. FDA also raised the issue of whether tumor reduction was due to nivolumab, RP1, or both. fda.gov This scientific uncertainty remains the main risk for the stock.

How is RP1’s safety record evaluated?

In the 140-patient group, 98% experienced adverse events of any grade. Grade 3 or higher adverse events were reported in 31% of patients, with 36% facing serious events. Adverse reactions led to discontinuation of treatment for 15.7%. fda.gov Five patients died following treatment-emergent adverse events, with varying assessments of causality. FDA found two deaths possibly connected to RP1 or nivolumab. Most frequent reactions included fatigue, fever, infection, chills, diarrhea, and nausea. fda.gov

For how long can Replimune support its operations, and is there a chance of dilution?

As of March 31, 2026, the reported cash and investments totaled $268.9 million. Operating cash burn for fiscal 2026 amounted to $280.3 million. The net loss for the year expanded to $313.9 million, up from $247.3 million. Replimune Group Inc. Management expects funds to last into the first quarter of 2027. Long-term debt was $83.3 million. SEC The 10-K indicates that future funding could involve equity, debt, or strategic partnerships, keeping dilution as an ongoing risk.

What is the potential size of RP1's initial commercial market?

Replimune projects that 13,000 U.S. patients experience disease progression following PD-1 therapy each year. The company assesses that around 80% of these could be suitable for RP1 combined with nivolumab. This calculation suggests approximately 10,400 individuals per year may be eligible for the combination. SEC This figure is a company estimate and has not been independently confirmed. Outpatient delivery may reduce the treatment burden and facilitate center uptake. Revenue remains contingent on label scope, pricing, reimbursement, and patient demand.

What do the newest Wall Street projections indicate?

The current average target stands at $11.50, just 2.7% higher than the Friday close. Out of eight analysts, the consensus rating is Hold. StockAnalysis Piper Sandler set a new target at $14, with Wedbush lifting its price objective to $12. Cantor Fitzgerald issued an upgrade but did not provide a revised target. StockAnalysis The new targets suggest potential gains from about 7% up to 25%. The average may include both outdated and updated projections. These estimates could be revised quickly following the FDA’s verdict.

What are the upcoming key catalysts?

The key event is the FDA’s target action date set for Sunday, August 2. If approved, market focus would turn to the specifics of the label, pace of launch, and reimbursement processes. If not approved, investor attention will revert to randomized IGNYTE-3 trial data and questions regarding funding. IGNYTE-3 continues to enroll patients, measuring overall survival as the main endpoint. Replimune Group Inc. The 280-patient REVEAL study may progress to Phase 2/3 as soon as early 2027. Initial RP2 liver-cancer readout is targeted for the end of 2026. SEC Strategic execution remains critical after the FDA decision.